RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
-11.86%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.23B
AUM Growth
-$140M
(-10%)
Cap. Flow
+$59M
Cap. Flow
% of AUM
4.8%
Top 10 Holdings %
Top 10 Hldgs %
29.04%
Holding
133
New
16
Increased
54
Reduced
20
Closed
13
Top Buys
| 1 |
STJ
St Jude Medical
STJ
|
$33.4M |
| 2 |
AET
Aetna Inc
AET
|
$25.1M |
| 3 |
Acadia Healthcare
ACHC
|
$19.9M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$18.4M |
| 5 |
CHMA
Chiasma, Inc. Common Stock
CHMA
|
$10.4M |
Top Sells
| 1 |
Medtronic
MDT
|
$42.2M |
| 2 |
THOR
THORATEC CORPORATION
THOR
|
$26.1M |
| 3 |
Humana
HUM
|
$25.2M |
| 4 |
McKesson
MCK
|
$14.7M |
| 5 |
Bausch Health
BHC
|
$13.7M |
Sector Composition
| 1 | Healthcare | 76.16% |
| 2 | Financials | 3.43% |
| 3 | Technology | 0.48% |
| 4 | Industrials | 0.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
BioMarin Pharmaceuticals
BMRN
$10.9B
| $5.32M | 0.43% |
50,500
+18,000
| +55% | +$1.9M |
|
|
CO
77
DELISTED
Global Cord Blood Corporation
CO
| $5.3M | 0.43% |
880,000
+50,000
| +6% | +$301K |
|
78
Regeneron Pharmaceuticals
REGN
$60.1B
| $5.12M | 0.42% |
11,000
| – | – |
|
|
KITE
79
DELISTED
Kite Pharma, Inc.
KITE
| $5.1M | 0.41% |
91,500
-26,500
| -22% | -$1.48M |
|
|
ATHN
80
DELISTED
Athenahealth, Inc.
ATHN
| $5.07M | 0.41% |
38,000
| – | – |
|
|
AIMT
81
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $5.06M | 0.41% |
+200,000
| New | +$5.06M |
|
82
Novavax
NVAX
$1.27B
| $5.06M | 0.41% |
35,750
| – | – |
|
83
Ascendis Pharma
ASND
$12B
| $4.78M | 0.39% |
270,000
+30,000
| +13% | +$531K |
|
84
Tandem Diabetes Care
TNDM
$837M
| $4.78M | 0.39% |
54,250
+750
| +1% | +$66.1K |
|
|
AGN.PRA
85
DELISTED
Allergan plc.
AGN.PRA
| $4.73M | 0.38% |
5,000
| – | – |
|
86
MacroGenics
MGNX
$123M
| $4.67M | 0.38% |
218,000
+80,500
| +59% | +$1.72M |
|
|
RLYP
87
DELISTED
RELYPSA INC COM
RLYP
| $4.67M | 0.38% |
252,000
+11,900
| +5% | +$220K |
|
88
TherapeuticsMD
TXMD
$12.5M
| $4.54M | 0.37% |
+15,500
| New | +$4.54M |
|
|
GNCA
89
DELISTED
Genocea Biosciences, Inc.
GNCA
| $4.45M | 0.36% |
+81,250
| New | +$4.45M |
|
|
CSLT
90
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $4.2M | 0.34% |
1,000,000
+200,000
| +25% | +$840K |
|
91
FibroGen
FGEN
$45.7M
| $4.17M | 0.34% |
7,600
| – | – |
|
|
PETX
92
DELISTED
Aratana Therapeutics, Inc.
PETX
| $4.1M | 0.33% |
485,000
+185,000
| +62% | +$1.57M |
|
|
ATYR
93
aTyr Pharma
ATYR
$536M
| $3.99M | 0.32% |
27,785
-1,393
| -5% | -$200K |
|
|
EPZM
94
DELISTED
Epizyme, Inc
EPZM
| $3.99M | 0.32% |
310,000
+3,500
| +1% | +$45K |
|
|
EGLT
95
DELISTED
Egalet Corporation
EGLT
| $3.95M | 0.32% |
+300,000
| New | +$3.95M |
|
|
BLUE
96
DELISTED
bluebird bio
BLUE
| $3.85M | 0.31% |
3,474
| – | – |
|
|
NVTA
97
DELISTED
Invitae Corporation
NVTA
| $3.68M | 0.3% |
510,000
+110,000
| +28% | +$794K |
|
98
Dynavax Technologies
DVAX
$1.17B
| $3.68M | 0.3% |
+150,000
| New | +$3.68M |
|
99
Assembly Biosciences
ASMB
$179M
| $3.55M | 0.29% |
30,917
+4,792
| +18% | +$550K |
|
100
Cidara Therapeutics
CDTX
$1.65B
| $3.5M | 0.28% |
13,750
+1,250
| +10% | +$318K |
|